MarkW wrote:Over 100,000 people have MS in the UK (MS Trust data) and the average lifetime cost of MS to UK plc is one million pounds per patient (Oxford Uni data). This is the financial case for investigating if treating CCSVI syndrome with balloon venoplasty slows or stops MS progression. Are MS experts listening with open minds ?
Mark- When Zamboni recommended that folks who get CCSVI treatment continue taking their disease modifying drugs, the challenge for getting CCSVI into trials and treatment was made much more difficult. Why should patients continue to take expensive, ineffective and dangerous drugs AND get an unproven treatment at additional cost?
If CCSVI treatment was presented as a more economical alternative "replacement" to current ms drug therapies, I think we might see insurers and national health care agencies take a more serious interest.
Here in the U.S., Ginelya, the latest ms drug, is hitting the marketplace at $48,000 per year, ongoing. Several private clinics in the U.S. are offering CCSVI diagnosis and treatment for $7,500.
Government health providers and private insurers are scrambling to find more affordable health care options. I think any efforts to promote CCSVI in the media should hammer on the potential cost savings.